Health Care [ 8/12 ] | Health Care Equipment & Supplies [ 44/75 ]
NYSE | Common Stock
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.
In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated.
It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.
Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 26 | 0.17 Increased by +143.19% | 0.06 Increased by +191.60% |
| Nov 6, 25 | 0.16 Increased by +420.00% | 0.03 Increased by +433.33% |
| Aug 7, 25 | 0.03 Increased by +160.00% | -0.00 Increased by +1.01 K% |
| May 5, 25 | -0.01 Decreased by -120.00% | 0.04 Decreased by -126.67% |
| Feb 13, 25 | -0.39 Decreased by -293.60% | 0.04 Decreased by -1.15 K% |
| Nov 7, 24 | -0.05 Increased by +79.17% | -0.06 Increased by +16.67% |
| Aug 8, 24 | -0.05 Increased by +28.57% | -0.02 Decreased by -150.00% |
| May 6, 24 | 0.06 Increased by +118.18% | -0.09 Increased by +166.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 115.99 M Increased by +19.20% | 2.43 M Increased by +114.72% | Increased by +2.09% Increased by +112.35% |
| Sep 30, 25 | 113.39 M Increased by +18.39% | 6.50 M Increased by +384.18% | Increased by +5.73% Increased by +340.05% |
| Jun 30, 25 | 112.97 M Increased by +15.26% | 1.34 M Increased by +163.41% | Increased by +1.19% Increased by +155.02% |
| Mar 31, 25 | 98.98 M Increased by +1.59% | -505.00 K Decreased by -106.70% | Decreased by -0.51% Decreased by -106.60% |
| Dec 31, 24 | 97.31 M Increased by +3.88% | -16.48 M Decreased by -314.67% | Decreased by -16.94% Decreased by -299.16% |
| Sep 30, 24 | 95.78 M Increased by +9.02% | -2.29 M Increased by +76.66% | Decreased by -2.39% Increased by +78.59% |
| Jun 30, 24 | 98.02 M Increased by +9.82% | -2.12 M Increased by +37.29% | Decreased by -2.16% Increased by +42.90% |
| Mar 31, 24 | 97.43 M Increased by +17.06% | 7.53 M Increased by +155.67% | Increased by +7.73% Increased by +147.55% |